Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study.

CONCLUSIONS: These preliminary results suggest that treatment with tolvaptan could improve early atherosclerosis and endothelial dysfunction markers and improve the mood in ADPKD patients (probably by the acting on endothelial cell and adipocyte V2 receptors).
PMID: 32957887 [PubMed - as supplied by publisher]

Source: Current Vascular Pharmacology - September 16, 2020 Category: Drugs & Pharmacology Authors: Lai S, Mangiulli M, Perrotta AM, Gigante A, Napoleoni L, Cipolloni E, Mitterhofer AP, Gasperini ML, Muscaritoli M, Cianci R, Giovannetti A, Falco F, Mastroluca D, Mazzaferro S Tags: Curr Vasc Pharmacol Source Type: research